announced on the 6th that the approval of the AIDS treatment ‘ACC008’ in China is imminent.
ACC008 is a product made with ‘ACC007’, which was approved last year, and tenofovir and lamivudine, the existing drugs prescribed for the treatment of AIDS, into a single complex tablet. It is said that there is no need to take other AIDS drugs, only ACC008 can be taken once a day, reducing the burden of taking and improving compliance.
There are currently four major AIDS drugs prescribed in China. They are all imported drugs, so they are expensive, and you have to buy them all yourself. ACC008 is the only single tablet drug produced in China, and it is expected to secure market share through price competitiveness.
ACC007, which started sales in China this year, is also listed in health insurance, and sales are expected to increase. Kainos Med is receiving technology royalties (royalties) from the sale of ACC007.
An official from Kainos Med said, “It seems that there will be positive news about the marketing approval from Longevity ID, a Chinese partner. He continued, “Once the ACC008 starts to be marketed, the growth of royalties that Kainos Med will receive through ACC007 and ACC008 will accelerate.”
Kainos Med is promoting the transfer of copyright and technology to countries other than China.
Reporter Han Min-soo [email protected]